{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:06:05Z","timestamp":1791345965333,"version":"4.3.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T00:00:00Z","timestamp":1446076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1846-0","type":"journal-article","created":{"date-parts":[[2015,10,29]],"date-time":"2015-10-29T04:07:08Z","timestamp":1446091628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["microRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1"],"prefix":"10.1186","volume":"15","author":[{"given":"Tomomi","family":"Fujii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinta","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Obayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,29]]},"reference":[{"key":"1846_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/bjc.2012.221","volume":"107","author":"S Miah","year":"2012","unstructured":"Miah S, Dudziec E, Drayton RM, Zlotta AR, Morgan SL, Rosario DJ, et al. An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer. 2012;107:123\u20138.","journal-title":"Br J Cancer"},{"key":"1846_CR2","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/j.ajpath.2012.01.034","volume":"180","author":"P Puerta-Gil","year":"2012","unstructured":"Puerta-Gil P, Garc\u00eda-Baquero R, Jia AY, Oca\u00f1a S, Alvarez-M\u00fagica M, Alvarez-Ossorio JL, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 2012;180:1808\u201315.","journal-title":"Am J Pathol"},{"key":"1846_CR3","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1242\/dev.02073","volume":"132","author":"I Alvarez-Garcia","year":"2005","unstructured":"Alvarez-Garcia I, Miska EA. microRNA functions in animal development and human disease. Development. 2005;132:4653\u201362.","journal-title":"Development"},{"key":"1846_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12935-014-0119-3","volume":"14","author":"DR Morais","year":"2014","unstructured":"Morais DR, Reis ST, Viana N, Piantino CB, Massoco C, Moura C, et al. The involvement of miR-100 in bladder urothelial carcinogenesis changing the expression levels of mRNA and proteins of genes related to cell proliferation, survival, apoptosis and chromosomal stability. Cancer Cell Int. 2014;14:119.","journal-title":"Cancer Cell Int"},{"key":"1846_CR5","doi-asserted-by":"publisher","first-page":"e0117809","DOI":"10.1371\/journal.pone.0117809","volume":"10","author":"Y Lei","year":"2015","unstructured":"Lei Y, Li B, Tong S, Qi L, Hu X, Cui Y, et al. miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells. PLoS One. 2015;10:e0117809.","journal-title":"PLoS One"},{"issue":"6","key":"1846_CR6","first-page":"1821","volume":"40","author":"T Yamasaki","year":"2012","unstructured":"Yamasaki T, Yoshino H, Enokida H, Hidaka H, Chiyomaru T, Nohata N, et al. Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. Int J Oncol. 2012;40(6):1821\u201330.","journal-title":"Int J Oncol"},{"key":"1846_CR7","first-page":"1967","volume":"27","author":"J Tao","year":"2012","unstructured":"Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, et al. microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep. 2012;27:1967\u201375.","journal-title":"Oncol Rep"},{"key":"1846_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1146\/annurev.biochem.68.1.729","volume":"68","author":"M Bernfield","year":"1999","unstructured":"Bernfield M, G\u00f6tte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparin sulfate proteoglycans. Annu Rev Biochem. 1999;68:729\u201377.","journal-title":"Annu Rev Biochem"},{"key":"1846_CR9","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ejca.2004.01.038","volume":"40","author":"D Mennerich","year":"2004","unstructured":"Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, Rosenthal A, et al. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer. 2004;40:1373\u201382.","journal-title":"Eur J Cancer"},{"key":"1846_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1309\/617DWB5GNFWXHW4L","volume":"121","author":"FP O\u2019Connell","year":"2004","unstructured":"O\u2019Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol. 2004;121:254\u201363.","journal-title":"Am J Clin Pathol"},{"key":"1846_CR11","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/j.1349-7006.2009.01174.x","volume":"100","author":"K Shimada","year":"2009","unstructured":"Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouji Y, Konishi N. Syndecan-1, a new target molecule involved in progression of androgen-independent prostate cancer. Cancer Sci. 2009;100:1248\u201354.","journal-title":"Cancer Sci"},{"key":"1846_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/path.4271","volume":"231","author":"K Shimada","year":"2013","unstructured":"Shimada K, Anai S, Fujii T, Tanaka N, Fujimoto K, Konishi N. Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells. J Pathol. 2013;231:495\u2013504.","journal-title":"J Pathol"},{"key":"1846_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bbrc.2014.11.056","volume":"456","author":"T Fujii","year":"2015","unstructured":"Fujii T, Shimada K, Tatsumi Y, Fujimoto K, Konishi N. Syndecan-1 responsive microRNA-126 and 149 regulate cell proliferation in prostate cancer. Biochem Biophys Res Commun. 2015;456:183\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1846_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.urology.2005.01.023","volume":"66","author":"IC Mitsogiannis","year":"2005","unstructured":"Mitsogiannis IC, Ioannou MG, Sinani CD, Melekos MD. Plasmacytoid transitional cell carcinoma of the urinary bladder. Urology. 2005;66:194.","journal-title":"Urology"},{"key":"1846_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.urology.2006.05.029","volume":"68","author":"K Shimada","year":"2006","unstructured":"Shimada K, Nakamura M, Ishida E, Konishi N. Urothelial carcinoma with plasmacytoid variants producing both human chorionic gonadotropin and carbohydrate antigen 19-9. Urology. 2006;68:891. e7-10.","journal-title":"Urology"},{"key":"1846_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/1066896907306847","volume":"16","author":"C Patriarca","year":"2008","unstructured":"Patriarca C, Di Pasquale M, Giunta P, Bergamaschi F. CD138-positive plasmacytoid urothelial carcinoma of the bladder. Int J Surg Pathol. 2008;16:215\u20137.","journal-title":"Int J Surg Pathol"},{"key":"1846_CR17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/030089161009600231","volume":"96","author":"A Demirovic","year":"2010","unstructured":"Demirovic A, Marusic Z, Lenicek T, Spajic B, Balicevic D, Tomas D, et al. CD138-positive plasmacytoid urothelial carcinoma of urinary bladder with focal micropapillary features. Tumori. 2010;96:358\u201360.","journal-title":"Tumori"},{"key":"1846_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000356420","volume":"58","author":"DL Olsen","year":"2014","unstructured":"Olsen DL, Anderson SR. Metastatic plasmacytoid urothelial carcinoma: a case report and review of the literature. Acta Cytol. 2014;58:108\u201312.","journal-title":"Acta Cytol"},{"key":"1846_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1349-7006.2009.01379.x","volume":"101","author":"K Shimada","year":"2010","unstructured":"Shimada K, Nakamura M, De Velasco MA, Tanaka M, Ouji Y, Miyake M, et al. Role of syndecan-1 (CD138) in cell survival of human urothelial carcinoma. Cancer Sci. 2010;101:155\u201360.","journal-title":"Cancer Sci"},{"key":"1846_CR20","first-page":"78","volume":"1","author":"H Tazaki","year":"1988","unstructured":"Tazaki H, Tachibana M. Studies on KU-1 and KU-7 cells as an in vitro model of human transitional cell carcinoma of urinary bladder. Hum Cell. 1988;1:78\u201383.","journal-title":"Hum Cell"},{"key":"1846_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0959-8049(99)00262-2","volume":"36","author":"X Garcia Del Muro","year":"2000","unstructured":"Garcia Del Muro X, Torregrosa A, Mu\u00f1oz J, Castellsagu\u00e9 X, Condom E, Vigu\u00e9s F, et al. Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer. Eur J Cancer. 2000;36:357\u201362.","journal-title":"Eur J Cancer"},{"key":"1846_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrc1697","volume":"5","author":"XR Wu","year":"2005","unstructured":"Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5:713\u201325.","journal-title":"Nat Rev Cancer"},{"key":"1846_CR23","doi-asserted-by":"publisher","unstructured":"Miyazaki S, Yamamoto H, Miyoshi N, Wu X, Ogawa H, Uemura M, et al. A cancer reprogramming method using microRNAs as a novel therapeutic approach against colon cancer : research for reprogramming of cancer cells by microRNAs. Ann Surg Oncol. 2014; doi: 10.1245\/s10434-014-4217-1 .","DOI":"10.1245\/s10434-014-4217-1"},{"key":"1846_CR24","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.urology.2004.01.009","volume":"63","author":"R Zigeuner","year":"2004","unstructured":"Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology. 2004;63:1079\u201383.","journal-title":"Urology"},{"key":"1846_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1097-2765(00)80275-0","volume":"2","author":"A Yang","year":"1998","unstructured":"Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, D\u00f6tsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305\u201316.","journal-title":"Mol Cell"},{"key":"1846_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0002-9440(10)64396-9","volume":"161","author":"MJ Urist","year":"2002","unstructured":"Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol. 2002;161:1199\u2013206.","journal-title":"Am J Pathol"},{"issue":"3","key":"1846_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/cas.12089","volume":"104","author":"T Fujii","year":"2013","unstructured":"Fujii T, Shimada K, Anai S, Fujimoto K, Konishi N. ALKBH2, a novel AlkB homologue, contributes to human bladder cancer progression by regulating MUC1 expression. Cancer Sci. 2013;104(3):321\u20137.","journal-title":"Cancer Sci"},{"key":"1846_CR28","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/onc.2010.526","volume":"30","author":"LD Roy","year":"2011","unstructured":"Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 2011;30:1449\u201359.","journal-title":"Oncogene"},{"key":"1846_CR29","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.cellsig.2014.06.004","volume":"26","author":"G Liao","year":"2014","unstructured":"Liao G, Wang M, Ou Y, Zhao Y. IGF-1-induced epithelial-mesenchymal transition in MCF-7 cells is mediated by MUC1. Cell Signal. 2014;26:2131\u20137.","journal-title":"Cell Signal"},{"key":"1846_CR30","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.canlet.2013.12.029","volume":"346","author":"V Gnemmi","year":"2014","unstructured":"Gnemmi V, Bouillez A, Gaudelot K, H\u00e9mon B, Ringot B, Pottier N, et al. MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt\/\u03b2-catenin pathway and interaction with SNAIL promoter. Cancer Lett. 2014;346:225\u201336.","journal-title":"Cancer Lett"},{"key":"1846_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.4161\/isl.25351","volume":"5","author":"T Tomita","year":"2013","unstructured":"Tomita T. PGP 9.5 immunocytochemical staining for pancreatic endocrine tumors. Islets. 2013;5:122\u20138.","journal-title":"Islets"},{"key":"1846_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1309\/AJCPRJP39MIDSGBH","volume":"134","author":"Y Akishima-Fukasawa","year":"2010","unstructured":"Akishima-Fukasawa Y, Ino Y, Nakanishi Y, Miura A, Moriya Y, Kondo T, et al. Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma. Am J Clin Pathol. 2010;134:71\u20139.","journal-title":"Am J Clin Pathol"},{"key":"1846_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3858\/emm.2008.40.6.709","volume":"40","author":"JE Kim","year":"2008","unstructured":"Kim JE, Koo KH, Kim YH, Sohn J, Park YG. Identification of potential lung cancer biomarkers using an in vitro carcinogenesis model. Exp Mol Med. 2008;40:709\u201320.","journal-title":"Exp Mol Med"},{"key":"1846_CR34","first-page":"882","volume":"1","author":"MZ Michael","year":"2003","unstructured":"Michael MZ, O\u2019 Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1:882\u201391.","journal-title":"Mol Cancer Res"},{"key":"1846_CR35","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1158\/0008-5472.CAN-05-1783","volume":"65","author":"MV Iorio","year":"2005","unstructured":"Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065\u201370.","journal-title":"Cancer Res"},{"key":"1846_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ccr.2006.01.025","volume":"9","author":"N Yanaihara","year":"2006","unstructured":"Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189\u201398.","journal-title":"Cancer Cell"},{"key":"1846_CR37","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1158\/0008-5472.CAN-07-0533","volume":"67","author":"KP Porkka","year":"2007","unstructured":"Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67:6130\u20135.","journal-title":"Cancer Res"},{"key":"1846_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4161\/rna.8.1.14259","volume":"8","author":"WC Cho","year":"2011","unstructured":"Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol. 2011;8:125\u201331.","journal-title":"RNA Biol"},{"key":"1846_CR39","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/ijc.25284","volume":"127","author":"M Kano","year":"2010","unstructured":"Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, et al. miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer. 2010;127:2804\u201314.","journal-title":"Int J Cancer"},{"key":"1846_CR40","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/onc.2012.61","volume":"32","author":"P Gao","year":"2013","unstructured":"Gao P, Xing AY, Zhou GY, Zhang TG, Zhang JP, Gao C, et al. The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene. 2013;32:491\u2013501.","journal-title":"Oncogene"},{"key":"1846_CR41","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/carcin\/bgs130","volume":"33","author":"PT Law","year":"2012","unstructured":"Law PT, Ching AK, Chan AW, Wong QW, Wong CK, To KF, et al. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis. 2012;33:1134\u201341.","journal-title":"Carcinogenesis"},{"key":"1846_CR42","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2004.05.174","volume":"22","author":"SJ Chatterjee","year":"2004","unstructured":"Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004;22:1007\u201313.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1846-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1846-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1846-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T02:48:13Z","timestamp":1567306093000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1846-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,29]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1846"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1846-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,29]]},"article-number":"818"}}